Andrea Bassi, Vincenzo Piccolo, Grazia Gallippi, Giuseppe Argenziano, Michela Magnano, Carlo Mazzatenta
{"title":"靶向JAK/STAT信号：鲁索利替尼乳膏治疗并发白癜风和盘状红斑狼疮。","authors":"Andrea Bassi, Vincenzo Piccolo, Grazia Gallippi, Giuseppe Argenziano, Michela Magnano, Carlo Mazzatenta","doi":"10.4081/dr.2025.10458","DOIUrl":null,"url":null,"abstract":"<p><p>Dear Editor, A 50-year-old Caucasian male presented with a 30-year history of facial vitiligo, primarily affecting the chin and the perioral and periorbital regions. He had undergone multiple treatments over the years, including targeted phototherapy, topical corticosteroids, and calcineurin inhibitors, with limited success. [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus.\",\"authors\":\"Andrea Bassi, Vincenzo Piccolo, Grazia Gallippi, Giuseppe Argenziano, Michela Magnano, Carlo Mazzatenta\",\"doi\":\"10.4081/dr.2025.10458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dear Editor, A 50-year-old Caucasian male presented with a 30-year history of facial vitiligo, primarily affecting the chin and the perioral and periorbital regions. He had undergone multiple treatments over the years, including targeted phototherapy, topical corticosteroids, and calcineurin inhibitors, with limited success. [...].</p>\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2025.10458\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2025.10458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus.
Dear Editor, A 50-year-old Caucasian male presented with a 30-year history of facial vitiligo, primarily affecting the chin and the perioral and periorbital regions. He had undergone multiple treatments over the years, including targeted phototherapy, topical corticosteroids, and calcineurin inhibitors, with limited success. [...].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
